Kamlesh Dave, MD
Family Medicine · Lagrange, KYNPI 1679599500
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by GSK at 25.5% of the total.
Across 121 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$572
- AbbVie$540
- Amgen$445
- Vanda Pharmaceuticals Inc.$237
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$152
- AstraZeneca$77
- plus $219 from 8 others
Across 2 payments — averaging $10,194 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$20K
What the payments were for
- Food & beverage$2,242100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $572 |
| AbbVie | 37 | $540 |
| Amgen | 23 | $445 |
| Vanda Pharmaceuticals Inc. | 11 | $237 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $152 |
| AstraZeneca | 5 | $77 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Exact Sciences | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $28 |
| Novo Nordisk | 1 | $21 |
| Pfizer | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,242 in reported general payments places this provider in the 70th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $120,018 |
| VraylarCariprazine Hcl | 62 | $114,505 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $85,629 |
| TrulicityDulaglutide | 52 | $72,561 |
| JardianceEmpagliflozin | 47 | $66,588 |
| JanuviaSitagliptin Phosphate | 53 | $60,582 |
| EliquisApixaban | 36 | $39,883 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 126 | $38,193 |
| MounjaroTirzepatide | 32 | $37,255 |
| EntrestoSacubitril/Valsartan | 23 | $29,684 |
| UbrelvyUbrogepant | 16 | $28,919 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 109 | $22,878 |
| Repatha SureclickEvolocumab | 15 | $21,152 |
| Praluent PenAlirocumab | 40 | $20,826 |
| QuliptaAtogepant | 15 | $20,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Ubrelvy, Qulipta, Linzess | $540 | $177,652106 claims |
| Novo NordiskOzempic | $21 | $120,018111 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta | $572 | $113,749218 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $28 | $109,81684 claims |
| PfizerEliquis, Abrysvo | $16 | $78,076162 claims |
| NovartisEntresto | $14 | $29,68423 claims |
| AstraZenecaSymbicort | $77 | $13,63241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Lagrange
- Christopher RhyneLouisville$933K
- John RichardLexington$226K
- James TurnboPaducah$124K
- Edward SchumannFlorence$79K
- Ronald KoffNew Castle$71K
- Suraj GathaniLouisville$69K
- Bradley GrayFlorence$51K
- Jackie KazeeAshland$45K
- Mandy WhittLouisville$38K
- Derek JonesAshland$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.